Skip to main content

GeneProt Becomes Maiden Licensee to OGS Automated-Proteomics Technology

NEW YORK, Feb. 8 - Oxford GlycoSciences on Friday said that GeneProt has licensed a pair of patents to its automated proteomics technology. 


The licenses, for US Patents Nos. 6,064,754 and 6,278,794, cover "the use of methods and apparatus for computer-assisted selection and robotic isolation of proteins following two‑dimensional separation," the companies said in a joint statement.


Under the terms of the seven-year, non-exclusive agreement, GeneProt, which becomes the first company to license the technologies, will pay OGS an up-front licensing fee of $1 million in cash and equity. The firm will also shell out additional annual payments that will depend on the status of patents in the US, Europe, and Japan. 


Other terms of the deal were not disclosed.


"This licensing agreement will give GeneProt the freedom to operate under the patents licensed for the provision of proteomics services," the companies said. "No transfer of technology, know-how or trade secrets will occur under the terms of this transaction."


On Thursday, UK-based OGS said it has opened a US office that will focus on specialty biopharmaceuticals. The new facility in Bridgewater, NJ, will be home to OGS' commercial team, headed by Lou Ferrari, vice president of global marketing.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.